Biosimilars: business opportunities beyond the EU and the US
|
|
- Conrad Barber
- 6 years ago
- Views:
Transcription
1 Biosimilars: business opportunities beyond the EU and the US Fernando de Mora, PhD, MBA Professor Department of Pharmacology, Therapeutics and Toxicology Universidad Autónoma de Barcelona SPAIN Universidad Autónoma de Barcelona 1
2 Biosimilars beyond the EU and the US Overlooking the WW regulatory scenario Regulation and market: a return ticket Opportunities and partnerships Summing up Overlooking the WW regulatory scenario Regulation and market: a return ticket Opportunities and partnerships Summing up Biosimilars beyond the EU and the US 2
3 The WW biologics regulatory scenario 3 regulatory zones Highly regulated: EU, USA, Japan, Canada, Australia BIOSIMILARS Not-highly regulated: Rest of the World Non-biosimilar-non -original Biologics (NON-SIMILIAR BIOLOGICS or NSB) Moderately regulated Lowly regulated The Non-Similar Biologics (NSB) regulation Low to moderate REGULATION NSB Non-innovative biological products Copy biotherapeutic products Non-original Biologics Intended copies Non-comparable biologics etc.. Not proven to be BIOSIMILARS DRIVERS Economic reasons (less resources) Patent protection (weak) Local industry (regional-international) More affordable Patients access Patients at a higher risk (than EU, US... patients) Ethical? Fair for the patient? 3
4 Non-similar biologics (NSB): Impact on public health? Difficult to assess Precarious PHARMACOVIGILANCE systems Praditpornsilpa K, Tiranathanagul K et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney International, 80, 88 92, 2011 Mohammad Amir S, Behrouz V, Shiva S et al. Neutralizing antibodies in multiple sclerosis patients on weekly intrasmuscular Avonex and biosimilar interferon beta-1ª (CinnoVVex): comparing results of measurements in two different laboratories. J Imm Met. 388: 46-48, 2013 Kikuzubam ( rituximab-like ) in México? Withdrawn from market Health alert The regulatory walk : A WW trend towards EMA/WHO (1) The Elephant s regulatory walk Towards EMA-like Regulatory pathway From 2008 To 2014 Awareness being raised (authorities + physicians) STILL A LONG WAY TO GO EMA as the reference agency for biosimilars Regulatory walk undertaken in many countries (Biosimilar Generic) 4
5 The regulatory walk : A WW trend towards EMA/WHO (2) Jordan Guatemala Saudi Arabia Egypt Chile ETC... Perú Brasil México Costa Rica Colombia Argentina India... EMA Took the lead WHO: Paves the way SBP guidelines (2010) Regulatory expectations & risk assessment (2014) Meetings (Seoul 2010) + OTHER NO Way back Increasing regulatory convergence Regulatory walk led by Emerging economies The World Bank data/figures: Large emerging economies with robust/emerging biotech industry: *...Share of growth of biologics in 2012 was 14.7% despite share of sales was 7,5%; the piece of the pie will get bigger in emerging markets... Latam Pharma Market Brasil: 15 billion $ US México: 12 billion $ US Venezuela: 6 billion $ US Argentina: 5 billion $ US Colombia: 5 billion $ US Chile: 1.8 billion $ US Perú: 1.2 billion $ US Ecuador: ~1 billion $ US Ongoing regulatory debate in those countries (and others): Located between low-regulated and high-regulated countries *Rickwood S, Di Biase S - IMShealth White Paper. Searching for Terra Firma in the Biosimilars and Non-Original Biologics Market ( 5
6 Biosimilars beyond the EU and the US Overlooking the WW regulatory scenario Regulation and market: a return ticket Opportunities and partnerships Summing up Regulation versus market (1) What is going on in non-highly regulated countries? Original biotech products Non-similar biologics (NSB) Biosimilars? Co-exist Very low penetration so far A different market scenario a different market debate Changes the market balance of power Changes players positioning Changes drivers and barriers to entry 6
7 Regulation versus market (2) Original products: viewed as safe and efficacious, but unaffordable NSB : viewed as affordable but clinically doubtful (by some) The perfect storm for biosimilars: less expensive than originators, but equally safe and efficacious However, biosimilars 20-30% discount still Non-affordable NSB WILL STILL ACCOUNT (FOR YEARS) FOR THE GLOBAL BIOLOGICS SALES IN THESE COUNTRIES Drives/Barriers to entry (1) Market actors perception Physicians outlook on biosimilars Perception on biosimilars build over last years as quality products - in relation to NSB (NO debate over biosimilars safety/efficacy) Innovator industry Position in favor of EMA-like biosimilar regulation / Share goals-interest with biosimilar companies Same concerns regarding NSB (share adversary ) Pharmacovigilance system, traceability...(awareness) May change in the mid-to-long run with biosimilars penetration (moving target) 7
8 Drivers/Barriers to entry (2) National Regulatory Authorities (NRA)? Moderate resistance (depends on country): - economic pressure / need patient access...what s the trade off? - protection of local-regional players (e.g. Brasil?) Economic rationale Medical rationale Need to acknowledge risk for the patient Regulatory effort in progress (not quite yet EMA-like) -Regulatory oversight needed (applied?) - Education-training to regulators...for dossier assessment - Lack of experience / knowledge of biosimilars among healthcare actors - Save elsewhere (e.g. do not re-do tests...) Overlooking the WW regulatory scenario Regulation and market: a return ticket Opportunities and partnerships Summing up Biosimilars beyond the EU and the US 8
9 Partnerships with local-regional industry: a market aim (1) *Non original market grows faster than innovator biologics*, But Non-similar biologics limited to 20% of the biologics market...share of growth of biologics in 2012 was 14.7% despite share of sales was 7,5%; the piece of the pie will get bigger in emerging markets... Source: IMS Health MIDAS, MAT way trade India China Brasil México Argentina Russia Etc. Alliances with local-regional industry: a market aim (2) 2-way partnership between EU-present biosimilar companies and local-international industrial partners PARTNERSHIP 1 Targeting low-to-medium regulated countries To optimize EU companies launch of biosimilars in emerging countries Europe PARTNERSHIP 2 Targeting highly regulated countries Alliance with Local international companies targeting highly regulated markets 9
10 PARTNERSHIP 1 Biosimilars launch in emerging economies Enter emerging countries (and less emerging countries) Niche for biosimilars positioning Less expensive than innovators + same safety/efficacy Substitutability/interchangeability? INN prescription / traceability? Pharmacovigilance? Debate triggered by biosimilar/innovator co. Alliances with local-regional industry for marketing / distribution (e.g. Oli-Med (Latam) / Celltrion) Sales force training + PV plan needed Regulatory alignment with EMA viewed as beneficial to local-regional players: agencies-government willingness towards EMA-like regulation PARTNERSHIP 2 local-regional players in highly regulated countries EMERGING COUNTRIES HAVE Biotech know how Financial robustness Government backup (Taiwan, México, Brasil...) EMERGING COUNTRIES SEEK Regulatory experience/know how Technical/analytical capabilities Marketing know how ( strategy?) Exponential increase of their market potential 10
11 Partnerships: a WIN-WIN strategy EU Biosimilar companies Partnerships with local-regional companies for biosimilar DEVELOPMENT*-MARKETING under EU / WHO standards Market reasons (global rather than local perspective): objective market (WW) / RETURN Consequences Medical impact: safety-to-efficacy profile Regulatory reasons (raise awareness): willingness of national agencies of emerging countries to comply with high regulatory standards *Added value of products already launched in those countries? Restudied for biosimilarity under EMA, hence lower risk? (Rough clinical preliminar assessment: ) Moving towards a convergent regulatory landscape Regulation influences market dynamics Agreements between EU-present Biosimilar companies & Local-regional industry beyond EU/US Market expecation force / influence REGULATORY CHANGE in low-to-medium regulated countries 11
12 Biosimilars beyond the EU and the US Overlooking the WW regulatory scenario Regulation and market: a return ticket Opportunities and partnerships Summing up Biosimilars: business opportunities beyond the EU and US SEEING BEYOND TOMORROW BUSINESS DEVELOPMENT POTENTIAL? Partnerships EU-present biosimilar companies - players from emerging countries : a strategic move towards market uptake and WW regulatory alignment - To launch biosimilars in emerging countries - To co-develop biosimilars and build a portfolio for highly regulated regions Partnerships will have a social-ethical impact: Patients rights European Commission (EC) and EU national governments: back EU biosimilar companies/partnerships to prevent the forecasted globalization of competition from companies from emerging markets? 12
13 Gracias Fernando de Mora, PhD, MBA Professor Department of Pharmacology, Therapeutics and Toxicology Universidad Autónoma de Barcelona SPAIN Universidad Autónoma de Barcelona 13
Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015
Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More informationBUSINESS AND REGULATORY ENVIRONMENT OF BIOPHARMACEUTICALS AND BIOSIMILARS IN LATIN AMERICA RICARDO IBARRA-CABRERA
BUSINESS AND REGULATORY ENVIRONMENT OF BIOPHARMACEUTICALS AND BIOSIMILARS IN LATIN AMERICA RICARDO IBARRA-CABRERA INBIOXICA INBIOXICA is a firm dedicated to transform ideas into innovative products and
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More informationBiosimilar medicines rising to the cost challenge
Chapter 3 Biosimilar medicines rising to the cost challenge Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationFresh Deciduous Fruit (Apples, Pears, and Grapes): World Markets and Trade
Fresh Deciduous Fruit (Apples, Pears, and Grapes): World Markets and Trade June 9 SUMMARY Global apple production is expected to expand percent and trade is expected to surge 5 percent in 8/9 due to strong
More informationMoving from volume to value in the generic business model
Moving from volume to value in the generic business model CPhI Pre-connect conference Frankfurt 23rd October 2017 Copyright 2016 QuintilesIMS. All rights reserved. Key drivers to 2021 Global growth moderating
More informationBIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS
BIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS George Dranitsaris B.Pharm. PhD Consultant in Health Economics and Biostatistics What is a Biosimilar? Protein based drugs are made
More informationBiosimilar medicines rising to the cost challenge
Chapter 3 Biosimilar medicines rising to the cost challenge Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar
More informationGlobal Biosimilar Development
Transforming Clinical Trials Global Biosimilar Development The PharmaVoice podcast that accompanies this whitepaper can be found at: pharmavoice.com/podcasts TERMINOLOGY Many terms have been used to describe
More informationGlobal Biosimilar Market Trends & Opportunities: 2015 Edition
Global Biosimilar Market Trends & Opportunities: 2015 Edition Global Biosimilar Market Trends & Opportunities: 2015 Edition BioPortfolio has been marketing business and market research reports from selected
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationGlobal Talent 2021: The Transformation of Labor Supply and Demand in World Markets
Global Talent 2021: The Transformation of Labor Supply and Demand in World Markets Adrian Cooper CEO and Chief Economist Oxford Economics acooper@oxfordeconomics.com October 2012 Global Talent 2021 key
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationwhat you need to know
ESMO 2017 INDUSTRY SATELLITE SYMPOSIUM A sector group Biosimilars for Oncologists FRIDAY 8 SEPTEMBER 2017 18:00-20:00 PAMPLONA AUDITORIUM, HALL 4 sss IFEMA, FERIA DE MADRID, MADRID, SPAIN The Biosimilar
More informationEU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers
Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation
More informationCURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE. The role of Biosimilar Medicines
CURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE The role of Biosimilar Medicines Marc A. Mahl, MD MBA(INSEAD) President, Medicines for Europe Baltimore, 05 th September 2018 patients quality
More informationRasha Sayed Salama, MD, PhD, UAE
GaBI Scientific Meetings 10 October 2018, Le Meridien Dubai, United Arab Emirates 2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars
More informationSugar: World Markets and Trade
United States Department of Agriculture Foreign Agricultural Service November 2018 Sugar: World Markets and Trade Record Stocks and Consumption Despite Lower Production 205 185 Production Consumption Stocks
More informationMEDICAL DEVICES STUDIES
AN OVERVIEW OF MEDICAL DEVICES STUDIES Outsourcing Trends & Regulatory Landscape in Europe and Latin America - whitepaper - MARKET & LANDSCAPE At Eurotrials, we work to deliver a best in class solution
More informationA Ten Year Strategic Outlook for the Global Flexible Plastic Packaging Market. Sample pages. Commodity Inside Ltd
A Ten Year Strategic Outlook for the Global Flexible Plastic Packaging Market Sample pages Chapter 1- Executive summary 1.1 Changes in the global flexible plastic packaging industry 1.2 Cost effectiveness
More informationEnergy in transition - navigating through uncertainty
Energy in transition - navigating through uncertainty Prof Dr Christoph Frei Secretary General & CEO World Energy Council Santa Cruz, Bolivia August 20, 2014 twitter: @chwfrei uncertainty en economy Brazil
More informationInternational management system: ISO on environmental management
International management system: ISO 14000 on environmental management Introduction In response to the growing interest from businesses in environmental standards, the International Standardization Institute,
More informationRegulations for Post Approval Changes of Biotherapeutics Needs and Opportunities
Regulations for Post Approval Changes of Biotherapeutics Needs and Opportunities Dr. Thomas Schreitmueller Head Regulatory Policy F. Hoffmann La Roche Ltd, Basel, Switzerland Innovative Clinical Trial
More informationStrategic Overview of the Biotechnology Industry
Strategic Overview of the Biotechnology Industry Cavan Redmond Executive Vice President General Manager Wyeth BioPharma Business Unit June 15, 2004 2003Wyeth. Risk and Innovation Create Opportunity Biotech
More informationElwyn Griffiths, DSc, PhD, UK
GaBI Educational Workshops 2 3 March 2016, Hacettepe University, Ankara, Turkey First Turkish Interactive Workshop on Regulation and Approval of SIMILAR BIOTHERAPEUTIC PRODUCTS/BIOSIMILARS Elwyn Griffiths,
More information2015 MERCER LIFE SCIENCES REMUNERATION SURVEY
2015 MERCER LIFE SCIENCES REMUNERATION SURVEY MAKE SMART COMPENSATION DECISIONS BY JOINING THE 2015 MERCER TOTAL REMUNERATION SURVEY FOR THE LIFE SCIENCES SECTOR THE LIFE SCIENCES REMUNERATION SURVEY PROVIDES
More informationGlobal management and control system of automatic doors for BRT systems (Bus Rapid Transit)
Global management and control of automatic doors for BRT s (Bus Rapid Transit) What is it? How does it work? What does it consist of? It is an integrated of automatic doors for BRT stations that synchronises
More informationHospira at a 5/20/2015. The World s Leading Provider of Injectable Drugs and Infusion Technologies
Sumant Ramachandra, MD, PhD SVP and Chief Scientific Officer Alliance for Health Reform May 20 th, 2015 Hospira at a glance The World s Leading Provider of Injectable Drugs and Infusion Technologies Market
More informationScience. People. Affordable and innovative medicines.
Science. People. Affordable and innovative medicines. Synthon is a company committed to delivering quality medicines at sustainable pricing through innovative science Science-driven innovation Good health
More informationSpirax SafeBloc TM. double block and bleed bellows sealed stop valve
Spirax SafeBloc TM double block and bleed bellows sealed stop Spirax SafeBloc TM a single solution for safe double isolation The Spirax SafeBloc TM is a safe isolation solution, with a unique space-saving
More informationRunning an RTB Network Across 10 Markets Publisher Opportunities ATTILA BARTA
Running an RTB Network Across 10 Markets Publisher Opportunities ATTILA BARTA Head Cadreon PROGRAMMATIC ADVERTISING THE SELLERS PERSPECTIVE The Strengths, Weaknesses, Opportunities and the Pitfalls for
More informationSugar: World Markets and Trade
United States Department of Agriculture Foreign Agricultural Service Sugar: World Markets and Trade May 218 Elevated in 218/19 Keeps Stocks High, Pressuring Prices Ending Stocks 2 18 16 14 12 1 8 6 4 Other
More informationFIFARMA Position: Transparency in regulatory decision making on the approval for biosimilar products
FIFARMA Position: Transparency in regulatory decision making on the approval for biosimilar products CASSS LATAM Forum, Sep 5-6, Mexico City Thomas Schreitmueller, Co-chair FIFARMA Regulatory and Biologics
More informationInterdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines
Interdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines Richard Dolinar, MD Chairman, Alliance for Safe Biologic Medicines Disclaimer The views and opinions expressed
More informationHEALTH WEALTH CAREER MERCER LIFE SCIENCES REMUNERATION SURVEY
HEALTH WEALTH CAREER MERCER LIFE SCIENCES REMUNERATION SURVEY MAKE SMART COMPENSATION DECISIONS BY JOINING THE 2016 MERCER TOTAL REMUNERATION SURVEY FOR THE LIFE SCIENCES SECTOR THE LIFE SCIENCES REMUNERATION
More informationRoche Position 1 on Similar Biotherapeutic Products Biosimilars
Roche Position 1 on Similar Biotherapeutic Products Biosimilars Similar Biotherapeutic Products Biosimilars Innovative biotherapeutic products (e.g.monoclonal antibodies) are losing market exclusivity,
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationCompetition in the off-patent biological market:
November 14th, 2018 ISPOR Europe, Barcelona Competition in the off-patent biological market: Policies for biosimilars in Europe Evelien Moorkens PhD researcher Market access biosimilars Promotors: prof.
More informationCo sourcing -> Shared sourcing
Co sourcing -> Shared sourcing Let s MEET 2 QUESTIONS 3 What to SHARE(or not)? What to REDUCE? What to EXPECT? 4 WHO WE ARE? 5 Talented Together PRÉSENTATION CORPORATE DE SOPRA Mars 2014 6 Présentation
More informationLife Science Challenges and Opportunities in Latin America
Life Science Challenges and Opportunities in Latin America Roy Bateman, Trifermed Latin America One Nucleus Meeting, 29 January 2014 Overview of Latin America Basic facts, healthcare issues and the Pharmaceutical
More informationRaymond James 34th Annual Institutional Investors Conference
Raymond James 34th Annual Institutional Investors Conference Thomas Werner, CFO March 5, 2013 Safe Harbor This material contains forward-looking statements within the meaning of the U.S. federal securities
More informationThe importance of interchangeability in the procurement of medications: Biosimilar case
The importance of interchangeability in the procurement of medications: Biosimilar case ALIMS Congres, Kragujevac, November 6, 2015 Prof. Borut Štrukelj, PhD Brief CV Current position: professor, Pharmaceutical
More informationGlobal Serialisation Developments and the Need for Convergence. Ulrike Kreysa, Vice-President, GS1 Global Office 3 rd June 2015
Global Developments and the Need for Convergence Ulrike Kreysa, Vice-President, GS1 Global Office 3 rd June 2015 Developments across the world Regulatory bodies need to address Public Health issues one
More informationStrategy and Outlook Annual General Meeting. Hubert Sagnières May 5, 2011
Strategy and Outlook 2011 Annual General Meeting Hubert Sagnières May 5, 2011 The Optical Market in 2011 A still significantly under-penetrated market A high ramp-up potential A growing, profitable mid-range
More informationIMPROVING SALES EFFECTIVENESS. John Kieffer Business Transformation Director
IMPROVING SALES EFFECTIVENESS John Kieffer Business Transformation Director Working from a Position of Leadership and Growth Global Sales: $26.6 Billion (65% International) Net Income: $4.0 Billion R&D
More informationBiosimilars contracting in the NHS. Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast
Biosimilars contracting in the NHS Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast Aim Introduction Managing the Medicine Budget in the NHS The Biosimilar Medicine Challenges Questions
More informationThe EU Market Environment for Biosimilar Medicines
1 The EU Market Environment for Biosimilar Medicines 12 th Annual IGPA Conference Sep 30-Oct 2, 2009 Montreal Suzette Kox Senior Director Scientific Affairs European Generic medicines Association 2 Outlines
More informationPyramid Research. Publisher Sample
Pyramid Research http://www.marketresearch.com/pyamidresearch-v4002/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST
More informationPyramid Research. Publisher Sample
Pyramid Research http://www.marketresearch.com/pyamidresearch-v4002/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST
More informationThe generics environment today
The generics environment today Sergio Napolitano EGA Director Legal Affairs and Trade 2 October 2015, Warsaw C O M PA N I E S N AT I O N A L A S S O C I AT I O N S EGA Membership GE (Hungary) SPMA (Slovenia)
More informationEnabling international research collaboration:
Enabling international research collaboration: New Zealand s experience with the Global Research Alliance (GRA) www.mpi.govt.nz Outline of presentation Background on the GRA What s worked well and why?
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationGLOBAL VIDEO-ON- DEMAND (VOD)
GLOBAL VIDEO-ON- DEMAND (VOD) HOW WORLDWIDE VIEWING HABITS ARE CHANGING IN THE EVOLVING MEDIA LANDSCAPE MARCH 2016 A CHANGING VIDEO-VIEWING LANDSCAPE Nearly two-thirds of global respondents say they watch
More informationPharmacovigilance for biotherapeutics: Partnering for patient safety
International Federation of Pharmaceutical Manufacturers & Associations Pharmacovigilance for biotherapeutics: Partnering for patient safety Fermin Ruiz de Erenchun IFPMA Biotherapeutics Group Chair (F.
More informationSustainable Energy - Regional Outlook for Latin America and the Caribbean
Sustainable Energy - Regional Outlook for Latin America and the Caribbean Fernando Ferreira Executive Secretary Sustainable Energy for All: What Works and What Needs Fixing? May 15, 2014 Moscow, RUSSIA
More informationGlobal Carbon Finance (GLOCAF) model
OFFICIAL-SENSITIVE Global Carbon Finance (GLOCAF) model PMR Technical Workshop on Post-2020 Mitigation Scenarios and Carbon Pricing Modelling Brasilia, 03 February 2016 Contents Introduction GLOCAF model
More informationTI Emerging Markets Logistics Index. A comparison of the world s major developing markets on a number of different metrics
A comparison of the world s major developing markets on a number of different metrics March 2010 About Transport Intelligence Headquartered in the UK, Ti is one of the world s leading providers of expert
More informationSustainable Competition:
Sustainable Competition: the Magic Formula to Align Public Health and Business Objectives for Access Adrian van den Hoven Director General Medicines for Europe Medicines For Europe VISION Medicines for
More informationU.S. Rice Market Faces Larger Supplies and Lower Prices in 2018/19; Global Trade Projected Another Record High
U.S. Rice Market Faces Larger Supplies and Lower Prices in 218/19; Global Trade Projected Another Record High 218 Rice Outlook Conference December 5-7, 218 Nathan Childs Economic Research Service USDA
More informationMERCER LIFE SCIENCES COMPENSATION SURVEY
HEALTH WEALTH CAREER MERCER LIFE SCIENCES COMPENSATION SURVEY ASIA PACIFIC MAKE SMART COMPENSATION DECISIONS BY JOINING THE MERCER TOTAL COMPENSATION SURVEY FOR THE LIFE SCIENCES INDUSTRY THE LIFE SCIENCES
More informationRegulatory harmonization of 3Rs in QC testing requirements for biological products - from the viewpoint of users. Iwona Wilk-Zasadna
Regulatory harmonization of 3Rs in QC testing requirements for biological products - from the viewpoint of users Iwona Wilk-Zasadna Overview 1) Why we are interested in alternatives to animal testing goal
More informationSeizing E-Government Opportunities: Assessment, Prioritization, & Action. June 12, 2001
Seizing E-Government Opportunities: Assessment, Prioritization, & Action June 12, 2001 Today s Topics Understanding E-Readiness Assessing Readiness for E-Government Learning from Successes Prioritizing
More informationMeeting of The Global Platform For Business and Biodiversity
Meeting of The Global Platform For Business and Biodiversity W World Business Council for Sustainable Development W / Ecosystems FACT Takeshi Takagi, Co-chair, Hitachi December 16 th, 2011 What is the
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationREFERENCE CODE GDHC1113CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1113CFR PUBLICATION DATE M AY 2013 PSORIASIS - Executive Summary Sales for Psoriasis in China 2012 2022 We estimate the 2012 PsO drug sales to be $392.2m in China. By forecast end in
More informationConsiderations for Global Development of Orphan Drugs. Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc.
Considerations for Global Development of Orphan Drugs Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc. 1 Disclosures Shareholder No Grant/research support No Consultant
More informationBiosimilars Clarified
Biosimilars Clarified 1 Learning Objectives Identify the key features of biological products and biosimilars Understand the biosimilar development pathway and clinical trials that assess biosimilarity
More informationfact sheet 3 Introduction to Biosimilars & Regulatory Requirements
3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation
More informationBiosimilars - more for less
Biosimilars - more for less Per Troein VP Strategic Partners, IMS Health 0 Agenda The Global trend for Biologicals An European overview of present status of biosimilars What can be learnt form Infliximab
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationPortable Oxygen Concentrators - Global Market Outlook ( )
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Portable Oxygen Concentrators - Global Market Outlook (2015-2022) Portable Oxygen Concentrators - Global Market
More information3 Italy Takes Its Innovation Strategy to a New Level with Collaborative Go-to-Market Plan for SMBs
CUSTOMER CASE STUDY 3 Italy Takes Its Innovation Strategy to a New Level with Collaborative Go-to-Market Plan for SMBs Executive Summary CUSTOMER NAME 3 Italy INDUSTRY Service Provider BUSINESS CHALLENGES
More informationGLOBAL MEDICAL DEVICE INDUSTRY OUTLOOK FOR 2018 Based on a survey of more than 4,200 industry professionals
GLOBAL MEDICAL DEVICE INDUSTRY OUTLOOK FOR 2018 Based on a survey of more than 4,200 industry professionals For more information, contact: Stewart Eisenhart Senior Regulatory Analyst marketing@emergogroup.com
More informationPuma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update August 9, 2018 Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements, including statements regarding the timing
More informationClimate Change, trade and production of energy-supply goods: The need for levelling the playing field Veena Jha
Climate Change, trade and production of energy-supply goods: The need for levelling the playing field Veena Jha Presentation at the WTO workshop on environmental goods and services. This presentation is
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationExperience with Serialization Implementation as one powerful measure to protect our patients. Françoise Hirth
Experience with Serialization Implementation as one powerful measure to protect our patients Françoise Hirth Objectives 1 2 3 Supply Chain integrity & product security A worldwide concern Pharma Industry
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationLabelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines
Labelling & Naming European Biosimilars Group (EBG) perspective >400 Million patient days worldwide clinical experience with EU biosimilar medicines Elke Grooten, Director Public Affairs Sandoz Europe
More informationWill the BRICs Decade continue? Prospects for trade and growth June 2011 Halle (Saale), Germany
Will the BRICs Decade continue? Prospects for trade and growth 23-24 June 2011 Halle (Saale), Germany Status and development in the dairy sector in the BRIC. Dr. Mikhail Ramanovich*, Dr. Asaah Ndambi**,
More informationInsights into the Evolving Pricing & Market Access Environment
Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those
More informationInvestigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations
More informationThe Potential For Litigation In New Era Of Biosimilars
The Potential For Litigation In New Era Of Biosimilars By Christian Frois, Richard Mortimer and Alan White; Analysis Group, Inc. Law360, New York (September 20, 2016, 4:06 PM EDT) Christian Frois Richard
More informationSolution Partner Program Global Perspective
Solution Partner Program Global Perspective SPACe 2012 Siemens Process Automation Conference Business Development Solution Partner Program Copyright Siemens AG 2012. All rights reserved Solution Partner
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationClimate Change, trade and production of energy supply goods: The need for levelling the playing field -Veena Jha
Climate Change, trade and production of energy supply goods: The need for levelling the playing field -Veena Jha Presentation at OECD seminar on the 10 th of May, 2009 Introduction Economic crisis implies
More information+50% Market share for biosimilar G-CSF 2
The Biosimilar Market Leader s Perspective Carol Lynch, Global Head of Sandoz Biopharmaceuticals April 28, 2016 10 years on, biosimilars have had a strong impact on global healthcare Product Approvals
More informationMedium Term Renewable Energy Market Report 2016
Medium Term Renewable Energy Market Report 2016 Clean Energy Investment and Trends IETA Pavilion COP22, Marrakech November 10, 2016 Liwayway Adkins Environment and Climate Change Unit International Energy
More informationHospira 2007 Investor Day. APAC Region. Tim Oldham, Ph.D. President, Asia-Pacific. Advancing Wellness. through the right people and the right products
Hospira 2007 Investor Day APAC Region Tim Oldham, Ph.D. President, Asia-Pacific Advancing Wellness through the right people and the right products The APAC Region Asia in Brief: 58% of the world s population
More informationHow to treat more patients and make money in emerging markets
1 How to treat more patients and make money in emerging markets AUTHOR Raja Shankar RShankar@imscg.com People buy innovative products in emerging markets. Millions of Brazilians, Russians, Indians, Chinese,
More informationBiosimilar regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) developments
Biosimilar regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) developments Ministry of Food and Drug Safety Jeewon Joung Outline I. Korean Regulatory Framework for Biosimilar
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationREFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug
More informationAccelerating Transformational Change: Opportunities and Barriers
Accelerating Transformational Change: Opportunities and Barriers Dr. Brian P. Flannery Major Economies Business Forum Business Engagement in Implementing NDCs and the Paris Agreement OECD Conference Center,
More informationWorld Energy Outlook Dr. Fatih Birol IEA Chief Economist 24 November 2010
World Energy Outlook 2010 Dr. Fatih Birol IEA Chief Economist 24 November 2010 The context: a time of unprecedented uncertainty The worst of the global economic crisis appears to be over but is the recovery
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com A REVIEW ON BIOSIMILAR DRUGS B. Vamseedhar Naik *1, M.
More informationCOMMITTEE ON COMMODITY PROBLEMS
September 2009 E COMMITTEE ON COMMODITY PROBLEMS JOINT MEETING OF THE FOURTH SESSION OF THE SUB-GROUP ON BANANAS AND THE FIFTH SESSION OF THE SUB-GROUP ON TROPICAL FRUITS Rome, 9 11 December 2009 PRODUCT
More informationCapillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective. Brian K. Nunnally, Ph.D.
Capillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective Brian K. Nunnally, Ph.D. Agenda The Lifecycle Approach a guidance review What it really means Global Emerging Markets and
More information